| David Griscom

The Los Angeles Times recently explored the high cost of fast tracking drugs at the Food and Drug Administration.

Top Cases | Genentech, Brian Shields, FDA, Thalidomide
| Anonymous (not verified)

Stryker will pay $80 million, $40 million under the False Claims Act, and subsidiary OtisMed, will be excluded from doing business with Medicare, Medicaid and other government health programs for 20 years, in exchange for the Deparment of Justice not criminally prosecuting Stryker for distributing knee surgery cutting guides after they were rejected by the FDA.

FCA | Joel Hesch, Stryker, OtisMed, FDA
Subscribe to FDA